Company intelligence / Profile preview

Candropharm

Cuijk, North Brabant, Netherlands

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Candropharm is a prominent European manufacturer and distributor of high-quality cannabinoid products, specializing in CBD, CBG, and CBN. Headquartered in the Netherlands, the company serves the global pharmaceutical, nutraceutical, and cosmetic industries with bulk ingredients and private label solutions. Candropharm distinguishes itself through rigorous quality standards, being the first European CBD company to achieve ISO 9001, ISO 22000, and ISO 13485 certifications. Their product portfolio is characterized by being THC-free, non-psychoactive, and produced using advanced extraction and purification technologies. The company also offers comprehensive contract manufacturing services, supporting clients from product development to final packaging.

Therapeutic areas: PsychiatryImmunologyNeurology
Modalities: Small molecule
Industry: Contract Manufacturing Organization

Beyond the preview

Go deeper on Candropharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Candropharm.

Explore the full profile